W Michael Korn
Overview
Explore the profile of W Michael Korn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
3439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arai H, Gandhi N, Battaglin F, Wang J, Algaze S, Jayachandran P, et al.
J Immunother Cancer
. 2024 Nov;
12(11.
PMID: 39500526
Background: In patients with colorectal cancer (CRC), the therapeutic effects of conventional immune checkpoint inhibitors targeting the adaptive immune system are largely limited to those with microsatellite instability-high tumors. Meanwhile,...
2.
Garcia-Murillas I, Cutts R, Walsh-Crestani G, Phillips E, Hrebien S, Dunne K, et al.
Breast Cancer Res Treat
. 2024 Oct;
209(3):493-502.
PMID: 39424680
Purpose: Detection of molecular residual disease (MRD) allows for the identification of breast cancer patients at high-risk of recurrence, with the potential that early initiation of treatment at early stages...
3.
Wang J, Xiu J, Battaglin F, Arai H, Soni S, Zhang W, et al.
NPJ Precis Oncol
. 2024 Sep;
8(1):214.
PMID: 39349771
Although histological and molecular classifications have been extensively studied for gastric cancer (GC), targeted therapies for GC remain limited. CDH1 mutations (MT) are characteristic of genomically stable GC and are...
4.
Chowdhury S, Xiu J, Ribeiro J, Nicolaides T, Zhang J, Korn W, et al.
Br J Cancer
. 2024 Sep;
131(8):1328-1339.
PMID: 39227409
Background: We developed a whole transcriptome sequencing (WTS)-based Consensus Molecular Subtypes (CMS) classifier using FFPE tissue and investigated its prognostic and predictive utility in a large clinico-genomic database of CRC...
5.
Hsu R, Al-Zubeidy B, Flores D, Nazarian A, Baugh A, Gonzalez E, et al.
Breast Cancer Res Treat
. 2024 Apr;
206(2):245-259.
PMID: 38643348
Purpose: Programmed death receptor ligand-1 (PD-L1) expression and tumor mutational burden (TMB) are approved screening biomarkers for immune checkpoint inhibition (ICI) in advanced triple negative breast cancer. We examined these...
6.
Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou F, et al.
Eur J Cancer
. 2024 Feb;
201:113914.
PMID: 38359495
Background: CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic...
7.
Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38212126
Background: The C-C motif chemokine receptor 5 (CCR5)/C-C motif chemokine ligand 5 (CCL5) axis plays a major role in colorectal cancer (CRC). We aimed to characterize the molecular features associated...
8.
Florou V, Elliott A, Bailey M, Stone D, Affolter K, Soares H, et al.
Clin Cancer Res
. 2023 Jun;
29(17):3408-3417.
PMID: 37266563
Purpose: Pure pancreatic acinar cell carcinomas (PACC) are rare malignancies with no established treatment. PACC demonstrates significant genetic intertumoral heterogeneity with multiple pathways involved, suggesting using targeted cancer therapeutics to...
9.
Hwang J, Shi X, Elliott A, Arnoff T, McGrath J, Xiu J, et al.
Clin Cancer Res
. 2023 May;
29(14):2702-2713.
PMID: 37126020
Purpose: In patients with metastatic prostate cancer (mPC), ATM and BRCA2 mutations dictate differences in PARPi inhibitor response and other therapies. We interrogated the molecular features of ATM- and BRCA2-mutated...
10.
Mondia M, Kritselis M, Donahue J, Elinzano H, Sarangi S, Bryant D, et al.
Front Neurol
. 2023 Jan;
13:1017087.
PMID: 36703629
Purpose: Epithelioid glioblastoma is an unusual histologic variant of malignant glioma. The present study investigates both the genomic and transcriptomic determinants that may promote the development of this tumor. Methods:...